Nasdaq Jumps 100 Points; US Trade Deficit Widens In September
Portfolio Pulse from Lisa Levin
US stocks traded higher with the Nasdaq Composite gaining over 100 points. The US trade deficit increased to $61.5 billion in September. TransMedics Group, Senti Biosciences, and Tharimmune saw their shares rise after positive news, while Ventyx Biosciences, Alto Ingredients, and Oportun Financial Corporation saw their shares drop due to disappointing results.
November 07, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shares of Senti Biosciences rose 70% after the company announced a new strategic collaboration with Celest Therapeutics.
Senti Biosciences announced a strategic collaboration with Celest Therapeutics, which has positively impacted its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Tharimmune shares rose 49% after the company disclosed an exclusive worldwide licensing agreement with Avior Bio.
Tharimmune disclosed an exclusive worldwide licensing agreement with Avior Bio, which has led to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
TransMedics Group shares rose 62% after reporting better-than-expected Q3 sales and strong FY23 revenue guidance.
TransMedics Group reported strong Q3 sales and issued a positive revenue guidance for FY23, which has led to a surge in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Shares of Alto Ingredients were down 58% after the company reported mixed third-quarter financial results.
Alto Ingredients reported mixed Q3 financial results, which has led to a drop in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Oportun Financial Corporation shares fell 45% after reporting a loss for the third quarter.
Oportun Financial Corporation reported a loss for Q3, which has negatively impacted its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Ventyx Biosciences shares dropped 81% after the company announced disappointing efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis.
Ventyx Biosciences announced disappointing efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis, which has negatively impacted its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100